The first and the best characterized strategy used in clinics is based on the inhibition of the interaction of programmed cell death 1 (PD1) present on the surface of T lymphocytes with its ligands PD-L1/CD274 and PD-L2/PDCD1LG2 expressed by tumor cells and antigen presenting cells [6]. Here, CD274 is linked to neoplasm.